Ọrịa kansa ọbara Lymphoblastic dị oke njọ (T-ALL)-08

Yesheng si Fujian kwuru sị, "A sị na m maara maka CAR-T na BIOOCUS Medical Group, m gaara abịa n'oge."

Na Septemba 2017, Yesheng nwere ihe ndị na-akpata ọnya ihu, nke na-agbasa nwayọ nwayọ ma jikọta ọnụ ka ọ bụrụ ntụpọ. Ka ọ na-erule Febụwarị 28, 2018, nyocha ọkpụkpụ gosiri "ọrịa leukemia lymphoblastic T-cell" mgbe e mechara ọtụtụ usoro ọgwụgwọ chemotherapy, yana nlele ndị na-adịghị mma n'oge ụfọdụ. A kwụsịrị ọgwụ niile na June 2019.

Na Mee 2021, Yesheng nwere oke ihe dị n'ime mpaghara ọnụ na pharyngeal yana oghere lymph olu buru ibu. Nnyocha ọzọ nke ụmị ọkpụkpụ gosiri na ọrịa leukemia amaliteghachila kpamkpam. Na Mee 28, e zigara Yesheng na Ngalaba Hematology nke Abụọ maka nnabata. Mgbe emechara nyocha zuru oke, a gbanwere nchọpụta ahụ ka ọ bụrụ "ọrịa leukemia dị oke njọ (T/myeloid biphenotypic)."

Otu usoro ọgwụgwọ chemotherapy emeghị ka ọkpụkpụ gbakee. Na Julaị 27, Yesheng natara ọgwụ mkpụrụ ndụ CD7 CAR-T, wee soro ya na ọgwụgwọ mkpụrụ ndụ CAR-T nke CD7. Ụbọchị iri na ise ka e tinyere ya, nyocha ọkpụkpụ gosiri na ọ nweghị ọrịa fọdụrụ, yana mmeghachi omume cytokine release syndrome (CRS) nke ọkwa 1 na enweghị mmeghachi omume ọjọọ na sistemụ akwara etiti.